2 Results Found

Advanced Search

Select all

Results per page

Select all

Review

2 Citations

1,796 Views

19 Pages

Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-Resistant Schistosoma Species

Sevan N. Alwan,
Alexander B. Taylor,
Stanton F. McHardy,
Michael D. Cameron and
Philip T. LoVerde

Pharmaceutics2025, 17(10), 1268;https://doi.org/10.3390/pharmaceutics17101268

27 September 2025

Schistosomiasis, a neglected tropical disease affecting over 250 million people worldwide, relies on praziquantel (PZQ) as its sole treatment. However, PZQ has significant limitations, including inactivity against juvenile worms, inability to prevent...

(This article belongs to the Section Drug Targeting and Design)

Full Article

Article

6 Citations

3,239 Views

18 Pages

Schistosome Sulfotransferases: Mode of Action, Expression and Localization

Meghan A. Guzman,
Anastasia Rugel,
Sevan N. Alwan,
Reid Tarpley and ,
Alexander B. Taylor,
Frédéric D. Chevalier,
George R. Wendt,
James J. Collins,
Timothy J. C. Anderson and
Philip T. LoVerde
+ 6 authors+ 1 author

Pharmaceutics2022, 14(7), 1416;https://doi.org/10.3390/pharmaceutics14071416

6 July 2022

Oxamniquine (OXA) is a prodrug activated by a sulfotransferase (SULT) that was only active against Schistosoma mansoni. We have reengineered OXA to be effective against S. haematobium and S. japonicum. Three derivatives stand out, CIDD-0066790, CIDD-...

(This article belongs to the Special Issue Development of Novel Pharmaceuticals for the Treatment of Parasitic Diseases)

Full Article